IntelGenx Technologies (IGXT) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IntelGenx Technologies reports promising preliminary results from its Phase 2a BUENA study on Montelukast VersaFilm® for treating mild to moderate Alzheimer’s disease, with a higher dose showing significant cognitive improvement. Despite overall mixed results, the 30-mg twice-daily dose of the buccal film demonstrated a notable benefit, prompting further research. The Alzheimer’s market is projected to grow substantially, indicating a strong potential for new therapies like IntelGenx’s repurposed Montelukast.
For further insights into IGXT stock, check out TipRanks’ Stock Analysis page.